Masimo Corporation (MASI)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 1,003,500 | 1,058,800 | 808,400 | 743,000 | 629,172 |
Revenue | US$ in thousands | 2,053,900 | 2,073,900 | 1,239,150 | 1,143,740 | 937,837 |
Gross profit margin | 48.86% | 51.05% | 65.24% | 64.96% | 67.09% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $1,003,500K ÷ $2,053,900K
= 48.86%
Masimo Corporation's gross profit margin has exhibited a declining trend over the past five years. In 2023, the gross profit margin decreased to 48.86% from 51.05% in 2022 and continued to lower compared to the levels seen in prior years. This decline indicates that the company's cost of goods sold has been increasing at a faster rate than its revenue, resulting in a lower percentage of sales retained as gross profit. It is essential for Masimo Corporation to closely monitor its cost structure and pricing strategies to improve its gross profit margin and overall profitability in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Masimo Corporation
MASI
48.86%
BioLife Solutions Inc
BLFS
25.21%
CONMED Corporation
CNMD
54.33%
LivaNova PLC
LIVN
70.50%
Medtronic PLC
MDT
25.96%
TransMedics Group Inc
TMDX
63.77%